Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
93 ^USD	+2.50%		+7.08%	+0.82%

Apr. 25	Transcript : Blueprint Medicines Corporation - Special Call
Mar. 22	Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	MT

Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024

February 15, 2024 at 07:00 am EST

Blueprint Medicines Corporation provided revenue guidance for the full year 2024. for the year, the company expects approximately $360 million to $390 million in global AYVAKIT net product revenues for all approved indications in 2024.

Latest news about Blueprint Medicines Corporation

Transcript : Blueprint Medicines Corporation - Special Call	Apr. 25
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	Mar. 22	MT
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	Mar. 01	MT
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety	Feb. 23	MT
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	Feb. 23	CI
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	Feb. 22	CI
Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating	Feb. 15	MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	Feb. 15	MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	Feb. 15	MT
Transcript : Blueprint Medicines Corporation, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q4 Revenue $72M, vs. Street Est of $67.1M	Feb. 15	MT
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024	Feb. 15	CI
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating	Feb. 13	MT
Oppenheimer Raises Blueprint Medicines Price Target to $90 From $85, Maintains Outperform Rating	Jan. 31	MT
Stifel Adjusts Blueprint Medicines' Price Target to $97 From $95, Keeps Buy Rating	Jan. 09	MT
Transcript : Blueprint Medicines Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 10:30 AM	Jan. 08
Wedbush Lowers Blueprint Medicines' PT to $97 From $100 After Discussion of Strategic Priorities for 2024, Pipeline Update; Keeps Outperform Rating	Jan. 08	MT
Raymond James Adjusts Blueprint Medicines' Price Target to $100 From $85, Keeps Strong Buy Rating	Dec. 22	MT
Wells Fargo Raises Blueprint Medicines Price Target to $115 From $86, Maintains Overweight Rating	Dec. 19	MT
Blueprint Medicines Insider Sold Shares Worth $395,350, According to a Recent SEC Filing	Dec. 13	MT
Blueprint Medicines Receives European Approval for Ayvakyt in Indolent Systemic Mastocytosis	Dec. 12	MT
Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis	Dec. 12	CI
Wedbush Raises Blueprint Medicines Price Target to $100 From $80, Maintains Outperform Rating	Dec. 11	MT
Blueprint Medicines Insider Sold Shares Worth $375,000, According to a Recent SEC Filing	Dec. 11	MT

Chart Blueprint Medicines Corporation

Duration

Period

More charts

Company Profile

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Blueprint Medicines Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

93 USD

Average target price

97.47 USD

Spread / Average Target

+4.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BLUEPRINT MEDICINES CORPORATION	+0.82%	5.84B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research